STIFEL FINANCIAL CORP - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 190 filers reported holding CRISPR THERAPEUTICS AG in Q2 2019. The put-call ratio across all filers is 1.08 and the average weighting 0.6%.

Quarter-by-quarter ownership
STIFEL FINANCIAL CORP ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$1,220,045
-24.7%
26,879
-6.9%
0.00%0.0%
Q2 2023$1,620,262
+21.3%
28,861
-2.3%
0.00%0.0%
Q1 2023$1,336,233
+9.7%
29,543
-1.4%
0.00%0.0%
Q4 2022$1,218,005
-36.1%
29,963
+2.7%
0.00%
-33.3%
Q3 2022$1,906,000
+35.8%
29,166
+26.3%
0.00%
+50.0%
Q2 2022$1,404,000
-33.5%
23,096
-31.3%
0.00%
-33.3%
Q1 2022$2,111,000
-5.2%
33,625
+14.4%
0.00%0.0%
Q4 2021$2,227,000
-43.8%
29,391
-17.0%
0.00%
-50.0%
Q3 2021$3,965,000
+9.3%
35,422
+58.0%
0.01%
+20.0%
Q2 2021$3,629,000
+32.4%
22,418
-0.3%
0.01%0.0%
Q1 2021$2,740,000
+6.5%
22,490
+33.9%
0.01%0.0%
Q4 2020$2,572,000
+143.3%
16,801
+33.0%
0.01%
+150.0%
Q3 2020$1,057,000
+20.9%
12,635
+6.2%
0.00%0.0%
Q2 2020$874,000
+67.4%
11,893
-3.2%
0.00%
+100.0%
Q1 2020$522,000
-26.0%
12,281
+6.2%
0.00%0.0%
Q4 2019$705,000
+76.2%
11,562
+18.0%
0.00%0.0%
Q3 2019$400,000
+0.3%
9,795
+18.0%
0.00%0.0%
Q2 2019$399,0008,3040.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q2 2019
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$32,581,00055.55%
NEA Management Company, LLC 1,590,002$103,907,0005.19%
ARK Investment Management 8,237,122$538,296,0003.75%
Nikko Asset Management Americas, Inc. 4,262,736$277,078,0003.54%
CLOUGH CAPITAL PARTNERS L P 414,767$27,105,0002.89%
Integral Health Asset Management, LLC 220,000$14,377,0002.79%
PLUSTICK MANAGEMENT LLC 50,000$3,268,0002.48%
HC Advisors, LLC 53,944$3,525,0002.43%
Green Alpha Advisors, LLC 27,466$1,795,0001.52%
EFG Asset Management (North America) Corp. 84,356$5,516,0001.28%
View complete list of CRISPR THERAPEUTICS AG shareholders